{"schema_version":"secwatch.filing_event.v1","accession":"0001601830-23-000065","form_type":"8-K","ticker":"RXRX","cik":"0001601830","company_name":"RECURSION PHARMACEUTICALS, INC.","filed_at":"2023-10-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.723461+00:00","generated_at":"2026-06-10T06:22:19.781164+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Roche exercises oncology option under Recursion collaboration; triggers undisclosed fee","bullets":["Roche exercised Validated Small Molecule Option for a Small Molecule Validation Program in a single oncology area.","Option exercised on September 28, 2023; Roche to pay a Validated Small Molecule Option Fee per the agreement.","This is under the Collaboration and License Agreement between Recursion, Genentech Inc., and F. Hoffmann-La Roche Ltd dated December 5, 2021.","Fee amount not disclosed; option represents milestone in the existing partnership."],"urls":{"canonical":"https://secwatch.observer/filing/0001601830-23-000065","json":"https://secwatch.observer/filing/0001601830-23-000065.json","markdown":"https://secwatch.observer/filing/0001601830-23-000065.md","text":"https://secwatch.observer/filing/0001601830-23-000065.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1601830/000160183023000065/0001601830-23-000065-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1601830/000160183023000065/rxrx-20230928.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T06:22:19.781164+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}